98 results about "Normal blood" patented technology

Provided is a method for estimating a factor causing an abnormality in coagulation of a blood sample. In the method, 1) a parameter Ps relating to a coagulation reaction in a sample S and a parameter Pm relating to a coagulation reaction in a sample M are calculated, 2) an estimation as to whether the sample S is coagulation-factor-inhibitor-positive is carried out on the basis of Ps, and 3) a sample S that is not estimated to be coagulation-factor-inhibitor-positive in 2) is estimated to be lupus-anticoagulant-positive or coagulation-factor-deficient on the basis of Pm or on the basis of Ps and Pm. The sample S is a test blood sample having an extended coagulation time, the sample M is a mixed sample of the sample S and a sample N, and the sample N is a normal blood sample. Ps is calculated on the basis of a measurement point or time at which a coagulation reaction curve or a coagulation speed curve of the sample S reaches a prescribed value, and Pm is calculated on the basis of a measurement point or time at which a coagulation reaction curve or a coagulation speed curve of the sample M reaches a prescribed value.

The invention provides a matrix type balloon dilatation catheter, and belongs to the technical field of balloon catheters. The balloon dilatation catheter comprises a catheter body and a balloon assembly, wherein a guide tip is arranged at the far end of the catheter body; the balloon assembly is arranged at the far end of the catheter body, the far end of the balloon assembly is adjacent to the near end of the guide tip, the balloon assembly is provided with a plurality of rows of balloon units arranged in the axial direction of the catheter body, each balloon unit is provided with a plurality of sub-balloon bodies arranged in the circumferential direction of the catheter body, and each sub-balloon body is used for being independently filled or contracted. The balloon assembly has a plurality of filling shapes; the technical problems that in the prior art, the overall filling shape of a balloon cannot be flexibly adjusted, normal blood vessels are prone to being damaged, and a patient feels uncomfortable obviously are mainly solved.

Coronary artery disease is the most common disease in the cardiovascular field and is also one of important factors causing death in the global range, and by conducting blood vessel segmentation and stenosis detection on coronary angiography images, doctors can diagnose the coronary heart disease more accurately. The invention provides a brand new deep learning architecture SAM-VMNet, and the model combines the powerful feature extraction capability of MedSAM and the linear complexity advantage of a visual state space model of VM-UNet, so that the model has higher reasoning speed and stronger data processing capability than Transformer, and higher segmentation accuracy and stability of coronary angiography images are realized. Moreover, a'dynamic queue 'is used for capturing the narrow part of the blood vessel, and the narrow part is compared with the normal blood vessel diameter before and after the narrow part, so that quantitative calculation of the blood vessel stenosis degree is realized. The algorithm is high in operation speed, and full-automatic blood vessel contour extraction and stenosis degree detection can be achieved. The kit can be applied to the clinical diagnosis process of coronary heart disease.

The invention provides a matrix type balloon dilatation system, and belongs to the technical field of balloon catheters. The system comprises a catheter, a balloon assembly, a filling medium storage part and a flow control part, the balloon assembly is arranged at the position, close to the far end by a set distance, of the catheter, the balloon assembly is provided with a plurality of rows of balloon units arranged in the axial direction of the catheter, and each balloon unit is provided with a plurality of sub-balloon bodies arranged in the circumferential direction of the catheter; each sub-balloon body is used for independently filling or scaling; the filling medium storage part is communicated with the near end of the catheter and is used for providing a filling medium for each sub-balloon body; the flow control part is communicated with the filling medium storage part and is used for controlling filling or scaling of each sub-balloon body according to the pressure in the balloon assembly; the technical problems that in the prior art, the overall filling shape of a balloon cannot be flexibly adjusted, normal blood vessels are prone to being damaged, and a patient feels uncomfortable obviously are mainly solved.

The utility model provides a radial artery paracentesis postoperation compression hemostasis braking device which comprises a fixing plate, fixing pieces and a pressurizing assembly, the fixing pieces and the pressurizing assembly are installed on the fixing plate, the two fixing pieces are arranged at the two ends of the fixing plate, and the pressurizing assembly is arranged between the two fixing pieces. The pressurizing assembly comprises a clamping piece used for being clamped outside a surgical limb of a patient and a pressing piece used for being pressed on a puncture point, the pressing piece is installed on the clamping piece, a containing space for containing the surgical limb is formed between the fixing plate and the clamping piece, and at least one part of the pressing piece stretches into the containing space; according to the device, at least the palm-to-forearm section of the operative limb is fixed to the fixing plate through the fixing piece, so that the wrist joint is braked, the braking effect is good, and movement of the operative limb is not affected; the pressing piece does not influence normal blood supply of an operation limb, the compression hemostasis effect of a puncture point is good, meanwhile, operation is easy, and the workload of medical staff can be reduced.

Provided herein are red blood cell control compositions comprising one or more populations of lysable hydrogel particles having an impedance that is substantially similar to the impedance of a human red blood cell of average diameter; and a population of hemoglobin molecules or a population of dye molecules that have substantially similar absorbance as hemoglobin; wherein (i) and / or (ii) are present in an amount that corresponds to a normal blood sample or disease state, or (i) and (ii) are present at a ratio that corresponds to a normal blood sample or disease state.

The invention discloses an animal blood pressure prediction model establishing method based on smell information. The animal blood pressure prediction model establishing method comprises the following steps that response signals are obtained through response of an electronic nose gas sensor array to feces smell of a hypertensive rat; detecting the blood pressure of the hypertensive rat of which the excrement smell is detected; extracting characteristic response signals from the excrement smell information, wherein the characteristic response signals comprise a response mean value, a steady-state value, an integral and a differential; principal component analysis and discriminant analysis are carried out on the extracted characteristic values, and qualitative discrimination is carried out in combination with the blood pressure states (hypertension and normal blood pressure) of the rats; the extracted characteristic values serve as independent variables, multivariate linear analysis, a multi-layer perceptron neural network and partial least squares regression analysis are carried out, and quantitative prediction is carried out on the blood pressure of the female rats and the male rats. By means of the method, rat blood pressure state judgment and blood pressure detection based on excrement smell are achieved, and the problems that invasive operation difficulty is large, conscious animal individual compliance is poor, external interference factors are large, and a large amount of manpower, material resources and financial resources are consumed are solved. And a basis is provided for rapid and non-invasive evaluation of experimental animals.

The utility model discloses a balloon dilatation catheter with a double-cannula structure, relates to the technical field of medical instruments, and solves the technical problem that far-end myocardium or tissue ischemia of a patient is easily caused when a balloon of the balloon dilatation catheter is kept in a dilatation state for a long time. Comprising an outer tube, an inner tube penetrating through the outer tube and a balloon arranged on the outer tube in a sleeving mode, the outer tube is composed of a first outer tube body and a second outer tube body, the inner tube is composed of a first inner tube body and a second inner tube body, a transition part of an annular structure is installed between the first outer tube body and the second outer tube body, and a blood channel is formed in the transition part in the axial direction in a penetrating mode. The blood channel is communicated between the first inner tube and the second inner tube, and a guide wire is arranged in the blood channel, the first inner tube and the second inner tube in a penetrating mode. When the balloon is kept in an expansion state for a long time, blood of a patient can still penetrate through the balloon to supply blood to far-end myocardium or tissue, so that body injury caused by lack of normal blood supply to the patient is avoided.

The application discloses a kind of thrombus suction control method and thrombus suction device, and thrombus suction device includes suction assembly, suction assembly includes the shell with pressure cavity, piston rod and suction catheter, thrombus suction device also includes the motor of piston rod movement and the controller connected with motor, control method is: suction catheter is positioned to the blood vessel without thrombus, make motor operate according to speed V0, calibrate the pressure value B in pressure cavity under normal blood condition;Suction catheter is positioned to the blood vessel with thrombus, make motor operate according to speed V1, V1≤V0, make dynamic pressure value A0 in pressure cavity: when A0≤B, make motor keep speed V1 operation;When A0>B, make motor increase from speed V1: when B<A0≤C, make motor increase to speed V2 operation;When C<A0≤D, make motor increase to speed V3 operation;When D<A0≤E, make motor increase to speed V4 operation.The control method thrombus removal efficiency is high, and blood loss can be reduced.

The invention relates to a leukocyte product, frozen leukocytes, a preparation method and application of the leukocyte product and the frozen leukocytes in preparation of medicines for inhibiting inflammation. The leukocyte product comprises one or more non-viable leukocytes from blood, the non-viable leukocytes carry cytokine receptors but basically do not have proliferation capacity, and the cytokine receptors can be combined with cytokines which can be combined with normal blood leukocytes. The inactive leukocytes may be frozen leukocytes. The frozen leukocytes can be obtained by quickly freezing in-vitro normal blood leukocytes, and the quick freezing treatment temperature is ultralow temperature. The inactive leukocytes or frozen leukocytes in the leukocyte product can recognize and be competitively combined with the cytokines with normal immune cells without additionally secreting new cytokines, so that the cascade amplification effect of inflammation cannot be caused. The leukocyte product or frozen leukocyte can play an immunosuppressive role, has no obvious toxic or side effect, and can be used for preparing medicines for inhibiting inflammation, such as medicines for inhibiting severe inflammation.

The invention relates to the technical field of underground safety monitoring and occupational health protection, and discloses an eye movement and multi-mode sensing underground protective glasses and an early warning method. And an elevation angle eye movement sensing module, an inertial sensor, a PPG and body temperature galvanic skin sensor, an acoustic component, a wireless communication module and a detachable glasses leg battery module are connected. The method comprises the steps that eye images and multi-source physiological data are collected in real time, and a multi-dimensional state judgment model is constructed; the logic contradiction between normal blood oxygen value and slow eye movement response is innovatively used for recognizing hidden carbon monoxide poisoning, accidental slipping and coma falling are distinguished through a posture and eye movement cooperation mechanism, and meanwhile the active noise reduction function is achieved. The problems that traditional equipment cannot recognize hidden poisoning and the falling false alarm rate is high are solved, and accurate sensing and early warning of physiological fatigue, poisoning symptoms and safety states of underground personnel are achieved.

The present invention relates to the field of medical data processing technology, and specifically to an integrated medical-nursing-patient follow-up support system for preventing complications after TIPS surgery. The system comprises a data acquisition module, a complication risk expression degree acquisition module, and a risk warning module. The system is used to obtain the patient's normal blood ammonia level, heart rate, systolic blood pressure dispersion increase, average protein intake, and the postoperative stage to which they belong, obtain the patient's physical recovery degree at each follow-up time, and obtain a recovery state time series; obtain the patient's poor prognosis level, compensate for the poor prognosis level to obtain the patient's recovery risk coefficient; obtain the patient's physical sign risk coefficient, obtain the patient's complication risk expression degree, and provide an early warning of postoperative complication risks. The present invention aims to avoid the influence of the patient's recovery status and physical sign data when analyzing TIPS postoperative complications, thereby improving the accuracy of analyzing TIPS postoperative complications.

According to the bleeding cage and the blood pump thereof, the blood mixing loss can be reduced, the supporting strength is good, the whole bleeding cage is in a circular tube shape, a far-end opening of the bleeding cage forms a blood inlet, a bleeding opening and a flushing outlet are formed in the outer wall of the bleeding cage, and the bleeding opening and the flushing outlet are formed in the axial direction at intervals. Normal blood pumped by the blood pump flows out from the blood outlet, and flushing fluid flows out from the flushing outlet after flushing the gap, so that energy loss caused by blood mixing is reduced, and the hydraulic performance of the blood pump is improved; the bleeding cage has a certain length in the axial direction, and the bleeding opening and the flushing outlet are arranged at an interval, so that the overall structural strength of the bleeding cage is ensured, and the bleeding cage is prevented from being deformed due to stress; meanwhile, the turbulence influence generated when blood flows through the bleeding cage is reduced, stable rotation of the magnet is improved, and then the rotation stability of the whole blood pump is guaranteed.

The utility model discloses a structure capable of realizing urgent detection of a single blood smear, which comprises a support table, wherein an X-axis linear moving module is arranged on the support table; the slide urgent cabin is connected to the X-axis linear moving module and is driven by the X-axis linear moving module to move along the X-axis direction; a jacking hole is formed in the bottom surface of the slide urgent cabin; a lifting plate is arranged on the supporting table and located below the slide urgent cabin, jacking supporting columns are arranged on the top face of the lifting plate, a lifting mechanism is arranged on the supporting table, and the driving end of the lifting mechanism is connected to the lifting plate to drive the lifting plate to ascend and descend in the direction close to or away from the slide urgent cabin. The slide conveying table is close to or far away from the upper surface of the slide urgent cabin in the Y-axis direction. According to the utility model, the automatic urgent detection of a single blood smear can be realized without manually stopping or waiting for the scanning work of a normal blood smear by medical staff, so that the working intensity of the medical staff is reduced while the working efficiency is improved.

The utility model relates to the technical field of vein blood sampling, in particular to an anti-backflow vein blood sampling device. The utility model provides an anti-backflow vein blood sampling device which can effectively prevent blood from flowing back and ensure normal blood sampling work. An anti-backflow vein blood sampling device comprises a needle head, a connecting piece, a needle wing, a connecting pipe, a fixing assembly and the like, the connecting piece is connected to the left portion of the needle head, the needle wing is connected to the upper side of the right portion of the connecting piece, the connecting pipe is connected to the left side of the connecting piece, and the fixing assembly capable of being fixed to an arm is arranged on the connecting piece. After blood flows into the control cylinder, the blood flows into the conical thin film and the hard tube, the conical thin film and the hard tube are kept in linear communication and then flow out of the collecting head, and after the blood stops flowing into the conical thin film, the hard tube droops under the action of gravity to block the conical thin film, so that the blood can be effectively prevented from flowing back; and the effect of normal blood sampling work is ensured.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine preparation for preventing and treating hyperuricemia, which is prepared from the following raw materials by weight: 5-20g of gynostemma pentaphyllum, 10-20g of selaginella doederleinii hieron, 5-15g of berchemia lineate, 5-15g of parthenocissus parvifolia, 12-15g of lotus leaf, 12-15g of cassia seed, 12-15g of white paeony root and 3-6g of raw liquorice. The traditional Chinese medicine composition has no obvious influence on the normal blood sugar level, has stable hypoglycemic activity when being used by diabetes patients, cannot reduce the normal blood sugar state when being taken, can reduce the uric acid level, protect the kidney, improve the glomerular filtration rate and promote uric acid excretion, and can effectively treat, inhibit or prevent hyperuricemia.

Provided herein are red blood cell control compositions containing one or more populations of lysable hydrogel particles having an impedance that is substantially similar to the impedance of a human red blood cell of average diameter; and a population of hemoglobin molecules or a population of dye molecules that have substantially similar absorbance as hemoglobin; wherein (i) and / or (ii) are present in an amount that corresponds to a normal blood sample or disease state, or (i) and (ii) are present at a ratio that corresponds to a normal blood sample or disease state.

The invention relates to the technical field of medicines, and discloses an application of a traditional Chinese medicine composition in serum neurotransmitter, which comprises the following steps: selecting 6-8 weeks old mice to establish a normal model, a chronic fatigue syndrome model and a functional dyspepsia model; the method comprises the following steps: sampling blood from mice of a normal model, a chronic fatigue syndrome model and a functional dyspepsia model to respectively obtain a normal blood sample, a CFS blood sample and an FD blood sample, and performing protein precipitation operation to obtain normal deproteinized supernatant, CFS deproteinized supernatant and FD deproteinized supernatant; separating by using a reversed-phase chromatographic column, and then carrying out mass spectrometric detection to respectively obtain a normal serum neurotransmitter mass spectrogram, a CFS serum neurotransmitter mass spectrogram and an FD serum neurotransmitter mass spectrogram; and carrying out concentration value calculation and rhythm fluctuation analysis to respectively obtain a neurotransmitter function index and a rhythm stability quantitative score. Therefore, the action mechanism of the serum neurotransmitter of the traditional Chinese medicine composition can be clearly and quantitatively represented.

The present invention discloses a communication device for bridging vascular injuries, comprising a bridging tube, with connecting portions provided at both ends of the bridging tube, the connecting portions being provided between the blood vessel and the bridging tube; a branch tube being provided on the outer periphery of the bridging tube to provide a channel for blood vessel supply, the branch tube being provided perpendicular to the axis of the bridging tube; the connecting portion comprising a straight section and a tapered section, both of which are integrally formed; a connecting thread being provided on the outer periphery of the straight section, a connecting thread being provided on the inner sidewall of the end of the bridging tube, the straight section of the connecting portion being threadedly connected to the bridging tube; and the tapered section of the connecting portion being inserted into the blood vessel and fixed by adhesive. The communication device for bridging vascular injuries provided by the present invention has a reasonable structure and is easy to connect, effectively ensuring normal blood supply and avoiding limb ischemia, necrosis, and disability caused by insufficient blood supply.

The present invention discloses a cardiovascular dilator, which belongs to the technical field of medical devices. It comprises a syringe, a first dilator and a second dilator. The second dilator is provided with multiple layers of additional dilators, which are arranged at intervals along the axis direction of the second dilator; an air bag is arranged in the additional dilator; each layer of the additional dilator is composed of a plurality of elastic arc-shaped protrusions evenly distributed, and the arc-shaped protrusions of two adjacent layers of the additional dilator are staggered with each other, and a liquid outlet is arranged at the lower end of the second dilator. The second dilator of the cardiovascular dilator of the present invention performs preliminary dilation, and the additional dilator in the second dilator slowly dilates the blood vessels, which can effectively prevent damage to the blood vessels; channels are formed between the additional dilators, which effectively prevent blockage of the blood vessels, so that the blood vessels can still circulate normally while dilating, and the squeezed and crushed intravascular vegetation is taken out, making the operation of medical personnel easier, and the field of vision and operation space wider.

To provide methods for improving the cardiovascular function and treating a cardiovascular disease using recombinant ectonucleotide pyrophosphatase / phosphodiesterase (NPP1).SOLUTION: The present invention provides methods for improving the cardiovascular function in a human patient (e.g., reducing hypertension) and methods of treating a cardiovascular disease, by administering a recombinant human soluble ectonucleotide pyrophosphatase / phosphodiesterase (hsNPP1) or an active fragment or fusion protein thereof. In one embodiment, the improvement is a reduction in elevated blood pressure (e.g., a reduction in blood pressure higher than 140 / 90 millimeters of mercury (mmHg) to within a normal blood pressure range, namely, about 120 / 80 mm of mercury (mmHg)).SELECTED DRAWING: None

Provided is a method for selecting a blood specimen having a possibility of including a coagulation abnormality, the method including: acquiring a parameter Ps(X) based on a coagulation reaction curve Rs(i) or a primary differential curve Vs(i) thereof for a test blood specimen, where the test blood specimen is a blood specimen for which it has not been possible to decisively determine the presence of prolonged APTT, i is a measurement point or time, and X is a variable and is greater than 0; acquiring a parameter Pm(X) for a normal blood specimen; and acquiring an index S for the test blood specimen on the basis of formula (2), (2)', or (2)", where Fs(X) = Ps(X) − Ps(c) and Fm(X) = Pm(X) − Pm(c), or Fs(X) = Ps(X) / Ps(c) and Fm(X) = Pm(X) / Pm(c), a > 0 and a ≤ b, 0 < c ≤ M, and M is a maximum value of X.

The invention relates to the technical field of hemostatic materials, and provides chitosan-based in-situ self-gel powder as well as a preparation method and application thereof. The chitosan-based in-situ self-gel powder provided by the invention comprises modified chitosan-based powder and oxidized polysaccharide powder, the modified chitosan-based powder is prepared from poly (3-sulfopropyl methacrylate potassium salt) grafted chitosan and poly [2-(methylacryloyloxy)-ethyltrimethyl ammonium chloride] grafted chitosan. The chitosan-based in-situ self-gelling powder provided by the invention has an in-situ self-gelling function, can quickly absorb water to realize self-gelling under the triggering of body fluid or blood, has excellent wet tissue adhesion performance, is high in water absorption speed and good in hemostatic effect, is not influenced by a normal blood coagulation mechanism in a hemostatic process, and has good postoperative anti-adhesion performance; no chemical cross-linking agent is used in the preparation process of the chitosan-based in-situ self-gel powder, the chitosan-based in-situ self-gel powder has good biocompatibility and biodegradability, raw materials are easy to obtain, synthesis is simple, and the chitosan-based in-situ self-gel powder is economical and safe.

A blood cell analyzer (100) and a blood cell analysis method (300). The blood cell analysis method (300) comprises: aspirating a blood sample to be tested; preparing a first assay sample, and obtaining first optical information; preparing a second assay sample, and obtaining second optical information; generating a first white blood cell classification scattergram and a second white blood cell classification scattergram; based on the first white blood cell classification scattergram and the second white blood cell classification scattergram, determining a first count result of neutrophils in the blood sample to be tested; determining an actual distribution region of neutrophils from the first white blood cell classification scattergram; based on a reference neutrophil distribution region of a reference white blood cell classification scattergram of a normal blood sample, determining a segmented granulocyte distribution region from the actual distribution region; determining a second count result of cells falling within the segmented granulocyte distribution region; based on the first count result and the second count result, determining a count result of band granulocytes in the blood sample to be tested.

Provided are a branch artery reconstruction assist device and an SC branch-preferential aortic reconstruction system, the branch artery reconstruction assist device comprising a first stent body (20a), the first stent body (20a) comprising a bare stent portion (23a), and a cardiac proximal covered stent portion (21a) and a cardiac distal covered stent portion (22a) connected to both sides of the bare stent portion (23a), and a sealing membrane (219a, 229a) and at least one sealing membrane (229a) are provided inside both the cardiac proximal covered stent portion (21a) and the cardiac distal covered stent portion (22a). Two coated stents (211a, 212a, 221a) are provided, and the sealing membranes (219a, 229a) include first openings (213, 214, 222), which are connected to corresponding first ends of the coated stents (211a, 212a, 221a), and the second ends of the coated stents (211a, 212a, 221a) are connected to corresponding branch artery coated stents (216, 217, 218) to form branch channels, and pass through the bare stent portion (23a). The SC branch-priority aortic reconstruction system includes a branch artery reconstruction assist device and a second stent body (50a), and the second stent body (50a) and the first stent body (20a) cooperate to seal and isolate the lesion. This prevents end leaks from the stent, ensures smooth access to each artery, and ensures normal blood flow to the brain and / or organs during surgery, avoids blood flow blockage, and reduces ischemic complications.

The invention discloses a hemostatic peptide capable of targeting to a bleeding focus as well as a preparation method and application of the hemostatic peptide, and the hemostatic peptide is characterized in that the amino acid sequence of the hemostatic peptide is RKLFFVRTA. According to the present invention, the key amino acid sequence combined with TF in the blood coagulation factor VII (FVII) is adopted as the basis for modification, the exposed TF (blood coagulation starting factor) after the blood vessel injury is specially identified, the specific expression of the TF at the bleeding site is adopted to achieve the precise targeting, the interference on the normal blood vessel is reduced, and the unnecessary thrombus risk is reduced from the source.

The invention discloses a recombinant fusion protein and application thereof in preparation of anti-gastric cancer angiogenesis medicines, and relates to the technical field of biological medicines. The amino acid sequence of the recombinant fusion protein is as shown in SEQ ID NO. 1. According to the invention, the amino acid sequence of the gastric cancer vascular targeting peptide CNTGSPYEC and the potent vascular inhibitor Endostatin gene are recombined to construct the recombinant fusion protein, and the selective distribution capability of the targeting peptide is utilized to carry the anti-vascular drug Endostatin to be more specifically enriched in gastric cancer vascular endothelial cells, so that the anti-vascular effect and the anti-tumor effect are improved, and the tumor resistance of the gastric cancer vascular targeting peptide CNTGSPYEC is improved. Meanwhile, due to the fact that distribution of Endostatin in normal blood vessels and tissues is reduced, corresponding toxic and side effects can be reduced, and great significance is achieved for improving the current situation of gastric cancer anti-blood-vessel treatment.

The present invention has a normal blood pressure measurement mode in which a blood pressure measurement is performed according to a blood pressure measurement instruction, and a nighttime blood pressure measurement mode in which a blood pressure measurement is automatically started according to a predetermined schedule. When being switched by an mode operation unit from the normal blood pressure measurement mode to the nighttime blood pressure measurement mode, an algorithm for blood pressure calculation by an oscillometric method is switched and set from an algorithm for a sitting position to an algorithm for a supine position. A blood pressure value is calculated using an algorithm currently set for the blood pressure calculation by the oscillometric method.

Provided herein are red blood cell control compositions comprising one or more populations of cleavable hydrogel particles, the cleavable hydrogel particles having an impedance substantially similar to that of human red blood cells having an average diameter; and a population of hemoglobin molecules or a population of dye molecules having substantially similar absorbance to hemoglobin; wherein (i) and / or (ii) are present in an amount corresponding to a normal blood sample or disease state, or (i) and (ii) are present in a ratio corresponding to a normal blood sample or disease state.

The present invention provides non-human animals expressing human CFB protein or chimeric (e.g., humanized) CFB protein and methods for using the same. The present invention further provides a non-human animal genome, a humanized CFB gene, and cells, tissues, organs, or non-human animals containing the non-human animal genome and the humanized CFB gene. The non-human animals obtained in this application successfully express human CFB protein or humanized CFB protein, which can be cleaved by CFD, bind to C3b, and exert similar effects in the human body. Furthermore, the non-human animals obtained in this application have complete renal function, normal blood biochemical indicators, and, more remarkably, do not exhibit the potential diseases observed in other transgenic mice known in this art.